LB Pharmaceuticals

The firm is developing a transdermal patch formulation of risperidone for once-weekly administration. Risperidone is a generic atypical antipsychotic used widely in schizophrenia and bipolar disorder. The patch is designed to maintain steady plasma levels and provide a visual adherence check for caregivers.

Current long-acting options are primarily intramuscular injections administered every two to four weeks in a clinical setting. LB Pharmaceuticals' transdermal approach allows weekly at-home application without needles. The patch also eliminates first-pass liver metabolism, which the firm has stated may improve the side-effect profile compared to oral risperidone.

The company is pursuing approval through the FDA's 505(b)(2) pathway, which lets sponsors reference published literature and the agency's prior findings for the active ingredient rather than conducting a full de novo clinical program. This reduces development time and cost relative to a new chemical entity.

Schizophrenia relapse is overwhelmingly driven by medication non-adherence, which can exceed 50% within the first year of oral therapy. A weekly patch that caregivers can visually confirm has been applied directly addresses the adherence gap that oral tablets and self-administered regimens cannot solve.

No venture capital firms, institutional investors, or corporate partners have been publicly named in connection with LB Pharmaceuticals. The firm appears to operate with private, undisclosed funding, and no equity financing rounds are on public record.